期刊
JOURNAL OF PSYCHIATRIC RESEARCH
卷 44, 期 7, 页码 429-433出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jpsychires.2009.10.012
关键词
Tardive dyskinesia; Schizophrenia; S100B; Antipsychotic treatment
类别
资金
- Beijing Municipal Natural Science Foundation [7072035]
- Stanley Medical Research Institute [03T-459, 05T-726]
- Department of Veterans Affairs
- VISN 16
- Mental Illness Research, Education and Clinical Center (MIRECC)
- United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639]
Several studies show that calcium-binding protein S100B is increased in schizophrenia and may be involved in the pathogenesis of tardive dyskinesia (TD). We therefore compared serum S100B levels in normal controls (n = 60), schizophrenic patients with (n = 32) and without TD (n = 50). Assessments included the abnormal involuntary movement scale (AIMS) and the positive and negative syndrome scale (PANSS). Serum S100B levels were measured by enzyme-linked immunosorbent assay (ELISA). The results indicated that patients with TD had higher serum S100B levels than normals and those without TD. Serum S100B levels were positively correlated with AIMS scores in patients with TD. These data suggest that increased S100B levels may be related to neuro-degeneration, associated with TO pathophysiology. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据